SI-BONE, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8257041090
USD
19.24
-0.18 (-0.93%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About SI-BONE, Inc. stock-summary
stock-summary
SI-BONE, Inc.
Pharmaceuticals & Biotechnology
SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
Company Coordinates stock-summary
Company Details
471 El Camino Real Ste 101 , SANTA CLARA CA : 95050-4482
stock-summary
Tel: 1 408 2070700
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (38.42%)

Foreign Institutions

Held by 86 Foreign Institutions (9.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jeffrey Dunn
Chairman of the Board, President, Chief Executive Officer
Mr. Timothy Davis
Lead Independent Director
Mr. Mark Foley
Independent Director
Dr. John Freund
Independent Director
Ms. Jeryl Hilleman
Independent Director
Mr. Gregory Hinckley
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 696 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.64

stock-summary
Return on Equity

-13.95%

stock-summary
Price to Book

4.09